1. Scrip
  2. >>COVID-19

Why BerGenBio’s Bemcentinib Will Kick-Off UK’s COVID-19 ACCORD Program

New Direction For Phase II Anticancer Agent

 
• By John Davis

There is strong scientific rationale from US and UK research to support evaluating the selective AXL kinase inhibitor bemcentinib in the UK’s early-stage clinical study program, ACCORD, a new initiative to find potential COVID-19 therapies.  

Cell_Covid19_Red
• Source: Shutterstock

BerGenBio ASA’s AXL kinase inhibitor bemcentinib is currently being evaluated as a potential therapy in Phase II studies in acute myeloid leukemia and non-small cell lung cancer, so the reason for its selection as the first compound to be evaluated in the UK’s ACCORD program to find novel COVID-19 therapies may not be obvious at first sight.

But there is in fact strong scientific rationale to support bemcentinib being chosen for ACCORD. As BerGenBio’s CEO Richard Godfrey...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.